AI Article Synopsis
- A systematic review identified 334 unique biomarkers related to the efficacy of anti-PD-1 therapy in high-risk melanoma patients, with the neutrophil-to-lymphocyte ratio being the most frequently studied.
- Out of the biomarkers assessed, 59 were significantly linked to overall survival (OS), 51 to progression-free survival (PFS), and 44 to treatment response, highlighting their potential relevance in therapy outcomes.
- While several biomarkers show promise for predicting therapy effectiveness, further confirmatory studies are essential to establish their clinical applications and implications.
Article Abstract
Summarize the literature assessing biomarkers in predicting efficacy of anti-PD-1 therapy for patients with high-risk unresectable or metastatic melanoma. Relevant studies were identified via a systematic literature review. About 334 unique biomarkers or biomarker combinations were identified from 121 citations. Neutrophil-to-lymphocyte ratio was the most frequently studied biomarker, followed by C-reactive protein. Fifty-nine biomarkers were significantly associated with overall survival (OS), 51 with progression-free survival (PFS) and 44 with response. Twenty biomarkers were associated with both OS and PFS; two were associated with OS, PFS and response (MHC-II and tumor mutational burden). Numerous biomarkers could potentially predict the efficacy of anti-PD-1-based therapy for melanoma patients. However, confirmatory studies are needed as well as determination of implications for clinical decision-making.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2021-0154 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!